Cargando…
Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720
BACKGROUND: The most commonly used biomarkers to predict the response of breast cancer patients to therapy are the oestrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2). Patients positive for these biomarkers are eligible for specific therapies suc...
Autores principales: | Baldacchino, Shawn, Saliba, Christian, Petroni, Vanessa, Fenech, Anthony G, Borg, Nigel, Grech, Godfrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913630/ https://www.ncbi.nlm.nih.gov/pubmed/24460909 http://dx.doi.org/10.1186/1878-5085-5-3 |
Ejemplares similares
-
Differential Expression of the Sphingolipid Pathway Is Associated with Sensitivity to the PP2A Activator FTY720 in Colorectal Cancer Cell Lines
por: Sciberras, Peter, et al.
Publicado: (2021) -
FTY720-derivatives do not induce FTY720-like lymphopenia
por: Segura-Ulate, Ismael, et al.
Publicado: (2017) -
Predictive markers in cancer patient diagnosis, classification and prediction of therapy outcome using leukaemia as a model
por: Grech, Godfrey, et al.
Publicado: (2014) -
FTY720 attenuates excitotoxicity and neuroinflammation
por: Cipriani, Raffaela, et al.
Publicado: (2015) -
New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth
por: Alshaker, Heba, et al.
Publicado: (2017)